Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadruple live Lactobacillus vaginal capsule
- Development stage
- Unknown
- Lead developer
- Beijing Tsinghua Changgung Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Quadruple live Lactobacillus vaginal capsule is a live biotherapeutic product (LBP) containing four distinct strains of live *Lactobacillus* bacteria. It is currently in Phase II clinical development for the treatment of bacterial vaginosis (BV), a condition characterized by a depletion of normal vaginal lactobacilli and an overgrowth of anaerobic pathogens. Administered intravaginally, the product is designed to restore a healthy, lactobacillus-dominant vaginal microbiota. By replenishing these beneficial bacteria, the treatment aims to lower vaginal pH and produce antimicrobial substances such as lactic acid and hydrogen peroxide, thereby inhibiting the growth of BV-associated pathogens. A multi-center, randomized, double-blind Phase II trial (ChiCTR2200058973) is evaluating the safety and efficacy of different doses of this quadruple formulation compared to standard oral metronidazole therapy.
- Other names
- quadruple Live Lactobacillus capsule四联乳杆菌活菌阴道胶囊
Beyond the preview
Go deeper on quadruple live Lactobacillus vaginal capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadruple live Lactobacillus vaginal capsule.